ImmunoPrecise Antibodies (STU:TQB) EV-to-EBITDA : -0.60 (As of Apr. 27, 2025)

ImmunoPrecise Antibodies EV-to-EBITDA Chart

ImmunoPrecise Antibodies Annual Data
	Trend	Dec14	Dec15	Apr17	Apr18	Apr19	Apr20	Apr21	Apr22	Apr23	Apr24
EV-to-EBITDA		Get a 7-Day Free Trial					-125.50	-137.71	-12.06	-4.08	-2.50

ImmunoPrecise Antibodies Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
EV-to-EBITDA	Get a 7-Day Free Trial															-7.57	-2.50	-1.73	-1.34	-0.66

Competitive Comparison of ImmunoPrecise Antibodies's EV-to-EBITDA

For the Biotechnology subindustry, ImmunoPrecise Antibodies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmunoPrecise Antibodies's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunoPrecise Antibodies's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ImmunoPrecise Antibodies's EV-to-EBITDA falls into.

ImmunoPrecise Antibodies EV-to-EBITDA Calculation

ImmunoPrecise Antibodies's EV-to-EBITDA for today is calculated as:

ImmunoPrecise Antibodies's current Enterprise Value is €18.19 Mil.
ImmunoPrecise Antibodies's EBITDA for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-30.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmunoPrecise Antibodies  (STU:TQB) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

ImmunoPrecise Antibodies's PE Ratio (TTM) for today is calculated as:

ImmunoPrecise Antibodies's share price for today is €0.382.
ImmunoPrecise Antibodies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.095.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

ImmunoPrecise Antibodies EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunoPrecise Antibodies Business Description